

**Mara Aspinall, M.B.A.** is a biotechnology executive with a focus in diagnostics and personalized medicine. Currently, President and Chief Executive Officer of On-Q-ity, Ms. Aspinall's prior position was President of Genzyme Genetics, a leading provider of diagnostic services in the oncology and reproductive markets. Ms. Aspinall created and implemented a new vision and strategy growing the business to one of the top five laboratories in the country. A key strategic focus was a renewed and disciplined emphasis on diagnostics research and development. Previously, Ms. Aspinall was President of Genzyme Pharmaceuticals and led that business' transformation from a generics manufacturer to a leader in specialized pharmaceutical manufacturing. Ms. Aspinall is an active leader in the public policy arena and in the current debate on personalized medicine. Ms. Aspinall is the Vice Chairman of the Personalized Medicine Coalition. Most recently, Ms. Aspinall co-authored an article published in the *Harvard Business Review* titled "Realizing the Promise of Personalized Medicine." A graduate of Tufts University and Harvard Business School, Ms. Aspinall launched her career at Bain and Company where she focused on strategy work for health care and information companies.